New
HealthMore in Health→
Daily Oral GLP-1 Orforglipron Linked to Similar Weight Loss Across Menopause Stages
Key Takeaways
- Analyses of the ATTAIN-1 and ATTAIN-2 trials, led by Dr. Hunter Thomas Hoffman of Eli Lilly, will be presented at the EASD annual meeting in Milan, Italy, Sept. 28–Oct. 2.
- Women taking orforglipron achieved significant, similar body weight reductions of up to 14% across premenopausal, perimenopausal and postmenopausal subgroups in both trials.
- Waist circumference fell by up to 12.5 cm (4.9 inches) in orforglipron subgroups, and up to 83% of treated women lost at least 5% of body weight versus 30% on placebo.
- Each menopausal subgroup receiving orforglipron or placebo contained between 142 and 225 women, and outcomes were assessed at 72 weeks.
DE
DT Editorial Team··via medicalxpress.com